On Thursday, Following U.S. Stocks were among the “Top Losers”: Scientific Games Corporation (NASDAQ:SGMS), Exelixis, Inc. (NASDAQ:EXEL), Akorn, Inc. (NASDAQ:AKRX), Cloud Peak Energy Inc. (NYSE:CLD)

Scientific Games Corp (NASDAQ:SGMS), with shares declined -9.21%, closed at $12.62.

Exelixis, Inc. (NASDAQ:EXEL), with shares dropped -8.19%, settled at $2.69.

Akorn, Inc. (NASDAQ:AKRX), with shares dipped -7.72%, and closed at $43.38.

Cloud Peak Energy Inc.(NYSE:CLD), plummeted -7.54%, and closed at $6.13.

Latest NEWS regarding these Stocks are depicted underneath:

Scientific Games Corporation (NASDAQ:SGMS)

Scientific Games Corporation (SGMS), stated financial results for the fourth quarter and year ended December 31, 2014. During the fourth quarter, Scientific Games accomplished the attainment of Bally Technologies, Inc. (“Bally”), creating a customer-focused, innovative gaming entertainment and technology supplier of player-appealing content and world-class systems and technologies for gaming, lottery and interactive operators worldwide. Unless otherwise noted, all results for the 2014 fourth quarter and full year referenced herein comprise the results of operations of Bally for the 40 days following the closing of the attainment on November 21, 2014.

2014 Fourth Quarter Business Update:

Gaming Segment:

Financial results and operating metrics presented below reflect Bally’s results of operations for the 40-day period following the closing of the attainment on November 21, 2014. Bally results are comprised of in the Corporation’s Gaming segment, except for results from Bally’s interactive products and services, counting Dragonplay Ltd., which are comprised of in the Interactive segment.

Gaming Segment Financial Highlights:

Proceed raised $149.8 million, principally due to $148.6 million from Bally in the 40-day post-attainment period, which comprised of $60.3 million in service proceed and $88.3 million in product sales proceed. The proceed raise also reflected a full quarter of WMS results (contrast to 74 days in the preceding-year period) and a favorable $7.1 million foreign currency translation influence, partially offset by lower WMS product sales proceed.

Gaming operations proceed raised $57.3 million reflecting the inclusion of Bally results for the 40-day post-attainment period and a full quarter of WMS results (contrast to 74 days in the preceding-year period).

The inclusion of 15,349 Bally WAP, premium and daily-fee units to the ending installed base was partially offset by a 935 unit decrease in the legacy Gaming installed base (i.e., that which pre-existed preceding to the Bally attainment), principally reflecting industry challenges throughout 2014. The legacy Gaming ending installed base declined 142 units on a quarterly sequential basis, primarily reflecting a 259-unit decline at a single multi-site casino customer’s facilities. The inclusion of Bally’s installed base of WAP, premium and daily-fee units led to a $14.62 per unit decrease in the average daily proceed to $58.28. The inclusion of 18,618 Bally units in the ending installed base of other leased and participation units was partially offset by a decrease of 2,040 units in the legacy Gaming business, primarily reflecting the loss of the Betfred contract in the U.K. at the starting of 2014. The addition of Bally’s installed base of other leased and participation units raised the average daily proceed by $2.00 per unit to $14.78.

Gaming machine sales proceed raised $47.3 million, as Bally generated $60.9 million for the 40-day post-attainment period, which was partially offset by $13.6 million in lower WMS-branded and other legacy Gaming product sales. New gaming machine sales proceed comprised of shipment of 6,100 units, counting 2,049 new Bally units and 2,002 new WMS units to U.S. and Canadian customers and 2,049 units to international customers, counting 1,052 Bally units and 997 WMS and SG Gaming UK units. Although total new unit shipments were lower on a pro forma combined basis for the full quarter, the Corporation believes its combined ship share, on a like-for-like basis, improved contrast to the preceding-year period. Other product sales proceed raised $7.9 million, inclusive of $5.4 million from Bally.

Lower shipments of WMS branded gaming machines to U.S. and Canadian customers reflected a decline of 500 units for new casino openings and Illinois VLT operators, partially offset by an raise of 301 units to 1,964 replacement units. The decline in international shipments principally reflected continued import restrictions in Argentina and lower sales in Mexico.

Gaming systems proceed raised $25.2 million and table products proceed raised $20.0 million, due primarily to the inclusion of Bally for the 40-day post-attainment period.

Operating loss raised $72.7 million as the higher proceed was more than offset by higher expenses, which comprised of the following:

Cost of product sales was unfavorably influenced by $17.8 million related to inventory write-downs related to certain suspended Gaming products as a result of the Bally attainment, $6.6 million related to the write-up to fair market value of Bally’s finished goods inventory in purchase price accounting and $2.1 million of non-cash inventory charges related to product obsolescence;

Cost of services comprised of $3.1 million of non-cash inventory charges for product obsolescence;

Selling, general and administrative expense comprised of $80.2 million from Bally for the 40 days post-closing of the attainment (inclusive of $41.0 million of charges related to the acceleration of Bally equity grants upon closing), in addition to $24.4 million for legal contingencies and settlements, $9.6 million in M&A and other charges, $6.0 million of impairment charges related to indefinite-lived intangible assets and an additional $4.0 million in incremental bad debt expense;

Research and development expense raised $17.5 million, counting $13.0 million from Bally for the 40-day post-attainment period;

Employee termination and restructuring costs reflected $11.3 million of charges primarily for employee separations; and,

Depreciation and amortization raised $68.5 million, counting $37.6 million in incremental depreciation and amortization related to Bally for the 40-day post-attainment period in addition to $27.8 million in charges related to long-term asset impairments and write-offs.

Scientific Games Corporation provides technology-based products and services, and associated content for gaming and lottery markets worldwide. The corporation operates in three segments: Instant Products, Lottery Systems, and Gaming.

Exelixis, Inc. (NASDAQ:EXEL)

Formerly on February 24, Exelixis, Inc. (EXEL), stated financial results for the fourth quarter and full year of 2014 and offered an update on progress toward delivering upon its 2015 key corporate objectives and clinical development milestones, while on February 19, Exelixis, Inc. (EXEL), declared that the U.S. Food and Drug Administration (FDA) has accepted for review Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib for patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib is a specific MEK inhibitor that was discovered by Exelixis and is now the subject of a worldwide co-development contract between Exelixis and Genentech, a member of the Roche Group.

Exelixis, Inc. is a biopharmaceutical corporation committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases.

Akorn, Inc. (NASDAQ:AKRX)

Akorn, Inc. (AKRX), a leading specialty pharmaceutical corporation, declared several generic product launches that build on Akorn’s commitment to serve the corporation’s specialty generic customers and patients.

Adenosine Injection. Akorn launched Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials, on December 22, 2014. Akorn’s product is an AP-rated generic version of Astellas’ Adenoscan(R) Injection and is a pharmacologic stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

According to IMS Heath, sales of branded and generic versions of Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials were about $33 million for the 12 months ended January 31, 2015.

Dexmedetomidine Hydrochloride Injection. Akorn launched Dexmedetomidine Hydrochloride Injection, 200mcg/2mL single dose vials on March 3, 2015. Akorn’s product is an AP-rated generic version of Hospira’s Precedex(TM) Injection. Akorn’s Dexmedetomidine Hydrochloride Injection is a relatively selective alpha2-andrenergic agonist indicated for the sedation of non-intubated patients preceding to and/or during surgical and other procedures.

According to IMS Heath, sales of branded and generic versions of Dexmedetomidine Hydrochloride Injection were about $121 million for the 12 months ended January 31, 2015.

Dronabinol Capsules. Akorn launched Dronabinol Capsules, USP CIII in 2.5 mg, 5 mg and 10 mg strengths on February 2, 2015. Akorn’s product is an AB-rated version of Abbvie’s Marinol(R) Capsules and are indicated for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

According to IMS Health, sales of branded and generic versions of Dronabinol Capsules were about $132 million for the 12 months ended January 31, 2015.

Sulfamethoxazole and Trimethoprim Oral Suspension. Akorn re-launched Sulfamethoxazole and Trimethoprim Oral Suspension (SMZ), USP 200 mg/40 mg per 5 mL in cherry- and grape-flavored oral suspensions on December 15, 2014. Akorn’s product is an antibacterial combination product indicated to treat bacterial infections resulting in urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis in adults, Shigellosis, Pneumocystis jiroveci Pneumonia and traveler’s diarrhea in adults.

According to IMS Health, sales of SMZ were about $56 million for the 12 months ended January 31, 2015.

Akorn, Inc. is a specialty pharmaceutical corporation engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India where the corporation manufactures ophthalmic, injectable and specialty non-sterile pharmaceuticals.

Cloud Peak Energy Inc. (NYSE:CLD)

Cloud Peak Energy Inc. (CLD) stock lately hit its new 52-week low price of $6.07, showing unsatisfactory performance. On the other hand it lastly hit its new 52-week high of $22.43 on Apr 4, 2014. Till that date, the stock doesn’t show its much volatile performance to hit its new 52-week high. If we look at its 52-week changing percentage then it is -68.32%. The stock has the beta value of 1.32, and its shares outstanding are 60.62M. Its average volume (3 month)3 is calculated to be 1,822,300, however for ten days it is 2,241,820. At this time the mean analysts recommendation of the stock is 2.40. (where 1=Buy, 5=Sale).

Cloud Peak Energy Inc., through its auxiliaries, produces coal in the Powder River Basin (PRB) and the United States. The corporation operates through Owned and Operated Mines, Logistics and Related Activities, and Corporate and Other segments. It produces and sells sub-bituminous thermal coal with low sulfur content primarily to electric utilities operating in the United States and internationally.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.